CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Sponsor: Vanderbilt University Medical Center
This observational or N/A phase trial investigates CMV and Heart Transplant Infection and is currently ongoing. Vanderbilt University Medical Center leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting
-
Nov 2024 — Present [monthly]
Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Jun 2023 — Dec 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Jun 2023 [monthly]
Recruiting
-
Jan 2021 — Feb 2022 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2019 — Oct 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
May 2019 — Jul 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vanderbilt University Medical Center
- ViraCor Laboratories
For direct contact, visit the study record on ClinicalTrials.gov .